Payment overview · 2025
General Payments
$244.76
9 reported records · 8 companies
Healthcare provider profile · identity verified
Nathan Michael Thomas
Allopathic & Osteopathic Physicians|Family Medicine · DES MOINES, IA · NPI 1881044089
Verified facts
What the public records show
CMS Open Payments records show Nathan Michael Thomas received $244.76 in general payments during 2025 across 9 reported records.
INTUITIVE SURGICAL, INC. accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $80.80 | 33.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.86 | 18.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.87 | 11.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.04 | 8.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.47 | 8.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.68 | 8.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.54 | 6.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.50 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $244.76 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $80.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 170 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
170 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 708 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 466 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 421 | 123 |
| Omeprazole | Omeprazole | 365 | 98 |
| Lisinopril | Lisinopril | 321 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 71 |
| Losartan Potassium | Losartan Potassium | 260 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 48 |
| Ozempic | Semaglutide | 223 | 39 |
| Gabapentin | Gabapentin | 218 | 62 |
| Eliquis | Apixaban | 217 | 38 |
| Simvastatin | Simvastatin | 211 | 55 |
| Potassium Chloride | Potassium Chloride | 207 | 54 |
| Metformin Hcl | Metformin Hcl | 200 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 56 |
| Furosemide | Furosemide | 189 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 54 |
| Mounjaro | Tirzepatide | 170 | 24 |
| Benazepril Hcl | Benazepril Hcl | 152 | 46 |
| Tramadol Hcl | Tramadol Hcl | 139 | 35 |
| Farxiga | Dapagliflozin Propanediol | 129 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 118 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 42 |
| Carvedilol | Carvedilol | 108 | 29 |
| Trazodone Hcl | Trazodone Hcl | 104 | 31 |
| Meloxicam | Meloxicam | 102 | 33 |
| Mirtazapine | Mirtazapine | 99 | 22 |
| Allopurinol | Allopurinol | 97 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 22 |
| Pregabalin | Pregabalin | 92 | 22 |
| Metformin Hcl Er | Metformin Hcl | 91 | 27 |
| Montelukast Sodium | Montelukast Sodium | 90 | 20 |
| Jardiance | Empagliflozin | 88 | 21 |
| Xarelto | Rivaroxaban | 88 | 16 |
| Alprazolam | Alprazolam | 85 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 23 |
| Baclofen | Baclofen | 78 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 24 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 77 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 30 |
| Glimepiride | Glimepiride | 73 | 13 |
| Celecoxib | Celecoxib | 72 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 26 |
| Sertraline Hcl | Sertraline Hcl | 70 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 70 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 47 |
| Torsemide | Torsemide | 67 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 15 |
| Alendronate Sodium | Alendronate Sodium | 63 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 13 |
| Lorazepam | Lorazepam | 61 | 20 |
| Trulicity | Dulaglutide | 61 | 16 |
| Spironolactone | Spironolactone | 60 | 18 |
| Estradiol | Estradiol | 58 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 58 | 33 |
| Levetiracetam | Levetiracetam | 58 | 11 |
| Prednisone | Prednisone | 58 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 17 |
| Methylprednisolone | Methylprednisolone | 57 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 16 |
| Ondansetron Odt | Ondansetron | 52 | 20 |
| Humalog | Insulin Lispro | 51 | suppressed |
| Famotidine | Famotidine | 50 | 11 |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | suppressed |
| Ezetimibe | Ezetimibe | 47 | 13 |
| Telmisartan | Telmisartan | 46 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Linzess | Linaclotide | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Kerendia | Finerenone | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 16 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 35 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Finasteride | Finasteride | 33 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 14 |
| Topiramate | Topiramate | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Naproxen | Naproxen | 27 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 16 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Belsomra | Suvorexant | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Lacosamide | Lacosamide | 23 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 13 |
| Atenolol | Atenolol | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Zonisade | Zonisamide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Rufinamide | Rufinamide | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levocarnitine | Levocarnitine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lyumjev Kwikpen U-200 | Insulin Lispro-Aabc | 11 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $244.76 · 9 records | INTUITIVE SURGICAL, INC. | CAPLYTA, Da Vinci Surgical System, FANAPT, FREESTYLE LIBRE 3, HETLIOZ, Kerendia, MINIMED 780G, MOUNJARO, UBRELVY, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error